• 1. A novel pyrazole based single molecular probe for multi-analyte (Zn2+ and Mg2+) detection in human gastric adenocarcinoma cells
  Anamika Dhara,Nikhil Guchhait,Indrani Mukherjee,Abhishek Mukherjee,Subhash Chandra Bhattacharya RSC Adv. 2016 6 105930
• 2. Ferro- and anti-ferromagnetically coupled tetracopper(II) 2 × 2 homoleptic rectangular grids supported by both μ-O and μ-(N-N) bridges derived from a new pyrazole based polydentate Schiff base ligand–magneto-structural correlations and DFT calculation
  Somnath Roy,Tarak Nath Mandal,Anil Kumar Barik,Samik Gupta,Mohamed Salah El Fallah,Javier Tercero,Ray J. Butcher,Susanta Kumar Kar Dalton Trans. 2009 8215
• 3. An orthogonal ferromagnetically coupled tetracopper(ii) 2 × 2 homoleptic grid supported by μ-O4 bridges and its DFT study
  Somnath Roy,Tarak Nath Mandal,Anil Kumar Barik,Sachindranath Pal,Ray J. Butcher,Mohamed Salah El Fallah,Javier Tercero,Susanta Kumar Kar Dalton Trans. 2007 1229

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazole carboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Pyrazole carboxylic acids and derivatives

Recent Advances in the Research of 5-methyl-1H-pyrazole-3-carbohydrazide (CAS: 40535-14-6)

5-methyl-1H-pyrazole-3-carbohydrazide (CAS: 40535-14-6) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile pharmacological properties. Recent studies have explored its potential as a key scaffold in the development of novel therapeutic agents, particularly in the areas of antimicrobial, anticancer, and anti-inflammatory applications. This research brief aims to synthesize the latest findings on this compound, highlighting its molecular mechanisms, synthetic pathways, and therapeutic potential.

One of the most notable advancements in the study of 5-methyl-1H-pyrazole-3-carbohydrazide is its role as a precursor in the synthesis of biologically active derivatives. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that modifications to the carbohydrazide moiety could enhance its binding affinity to specific enzyme targets, such as cyclooxygenase-2 (COX-2) and histone deacetylases (HDACs). These modifications have shown promise in reducing inflammatory responses and inhibiting cancer cell proliferation, respectively. The study also reported a novel synthetic route for 5-methyl-1H-pyrazole-3-carbohydrazide derivatives, which improved yield and purity compared to traditional methods.

In the context of antimicrobial research, 5-methyl-1H-pyrazole-3-carbohydrazide has exhibited potent activity against a range of bacterial and fungal pathogens. A recent Antimicrobial Agents and Chemotherapy article highlighted its efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and Candida albicans. The compound's mechanism of action involves disrupting cell wall synthesis and inhibiting key metabolic enzymes, making it a promising candidate for overcoming antibiotic resistance. Furthermore, computational docking studies have identified specific interactions between the compound and microbial proteins, providing a foundation for future structure-activity relationship (SAR) studies.

Another area of interest is the compound's potential in neurodegenerative disease research. Preliminary in vitro studies have suggested that 5-methyl-1H-pyrazole-3-carbohydrazide derivatives can modulate oxidative stress pathways and reduce neuronal apoptosis. A 2024 preprint on bioRxiv reported that these derivatives could cross the blood-brain barrier and exhibit neuroprotective effects in models of Alzheimer's disease. While these findings are promising, further in vivo studies are needed to validate their therapeutic potential.

Despite these advancements, challenges remain in the clinical translation of 5-methyl-1H-pyrazole-3-carbohydrazide-based therapies. Issues such as pharmacokinetic stability, bioavailability, and potential off-target effects need to be addressed. Recent efforts have focused on optimizing the compound's physicochemical properties through structural modifications and formulation strategies. For instance, a 2023 patent application disclosed a nanoparticle-based delivery system designed to enhance the compound's solubility and targeted delivery.

In conclusion, 5-methyl-1H-pyrazole-3-carbohydrazide (CAS: 40535-14-6) represents a versatile and promising scaffold in drug discovery. Its applications span antimicrobial, anticancer, and neuroprotective therapies, supported by a growing body of preclinical evidence. Future research should prioritize translational studies to bridge the gap between laboratory findings and clinical applications. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to unlock the full potential of this compound.

• 262292-02-4(3-tert-butyl-1H-pyrazole-5-carbohydrazide)
• 304665-45-0(1-Methyl-1H-pyrazole-3-carbohydrazide)
• 395653-63-1(3-Cyclopropyl-1H-pyrazole-5-carbohydrazide)
• 59591-84-3(1H-indazole-3-carbohydrazide)
• 76312-30-6(1H-Pyrazole-3-carboxylic acid, 5-methyl-, 2-methylhydrazide)
• 33064-36-7(1H-Pyrazole-3-carboxamide)
• 89270-66-6(1H-Pyrazole-3-carboxylic acid, 5-methyl-, 2-(1-oxopropyl)hydrazide)
• 89270-63-3(1H-Pyrazole-3-carboxylic acid, 5-methyl-, 2-acetyl-1,2-dimethylhydrazide)
• 89270-62-2(1H-Pyrazole-3-carboxylic acid, 5-methyl-, 2-acetyl-1-methylhydrazide)
• 89270-59-7(1H-Pyrazole-3-carboxylic acid, 5-methyl-, 1,2-dimethylhydrazide)